Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Cidara Therapeutics, Inc. (CDTX)

Biological Products, (no Disgnostic Substances)

https://www.cidara.com

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

6310 NANCY RIDGE DRIVE, SUITE 101
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/15/2015

Market Cap

88,329,912

Shares Outstanding

90,430,000

Weighted SO

90,433,777

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

CTMX --.--%

CFRX --.--%

CLSD --.--%

GLYC --.--%

TCON --.--%

Beta

1.0090

Last Div

0.0000

Range

10.0-24.4

Chg

-0.0900

Avg Vol

38877

Mkt Cap

88329912

Exch

NASDAQ

Country

US

Phone

858 752 6170

DCF Diff

-2.3100

DCF

2.2580

Div Yield

0.0000

P/S

2.2610

EV Multiple

1.9749

P/FV

0.4374

Div Yield %

0.0000

P/E

-0.5045

PEG

-0.0233

Payout

0.0000

Current Ratio

4.2527

Quick Ratio

4.2527

Cash Ratio

4.1462

DSO

21.9471

DIO

0.0000

Op Cycle

21.9471

DPO

265.7079

CCC

-243.7608

Gross Margin

0.9195

Op Margin

-0.9323

Pretax Margin

-3.0212

Net Margin

-2.9058

Eff Tax Rate

0.0426

ROA

-0.6548

ROE

-4.0189

ROCE

-0.2724

NI/EBT

0.9618

EBT/EBIT

3.2406

EBIT/Rev

-0.9323

Debt Ratio

0.0248

D/E

0.0328

LT Debt/Cap

0.0208

Total Debt/Cap

0.0318

Int Coverage

0.0000

CF/Debt

-29.0186

Equity Multi

1.3240

Rec Turnover

16.6309

Pay Turnover

1.3737

Inv Turnover

0.0000

FA Turnover

8.3743

Asset Turnover

0.2254

OCF/Share

-27.3414

FCF/Share

-27.4131

Cash/Share

36.0160

OCF/Sales

-3.1941

FCF/OCF

1.0026

CF Coverage

-29.0186

ST Coverage

-81.9842

CapEx Coverage

-381.5902

Div&CapEx Cov

-381.5902

P/BV

0.4374

P/B

0.4374

P/S

2.2610

P/E

-0.5045

P/FCF

-0.7060

P/OCF

-0.4590

P/CF

-0.4590

PEG

-0.0233

P/S

2.2610

EV Multiple

1.9749

P/FV

0.4374

DPS

0.0000

Latest Headlines (EST)

Benzinga Jun 25, 00:00 Cidara Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Jun 25, 00:00 Cidara Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Apr 01, 20:56 Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire Inc. Oct 04, 20:30 Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire Inc. Aug 19, 21:12 Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer GlobeNewswire Inc. Dec 22, 07:30 Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Revenue Product Segmentation